The published OS model and resultant simulations can be leveraged to support Phase II design and predict expected OS and HR (based on early observed TGI data obtained in Phase II or Phase III studies), thereby informing important mRCC development decisions, e.g., Go/No Go and dose regimen selection.
September 1, 2015
Author(s): Laurent Claret, Francois Mercier, Brett Houk, Peter Milligan, Rene Bruno
Year: September 1, 2015
Recommended for you